Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

European Research Council grant · Finished

NOVA Next Generation Polymyxin Antibiotics: Optimization and Validation

Coordinator
Universiteit Leiden, Netherlands
Runs
1 November 2022 to 30 April 2024
Status
Finished
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101082241

What the project is doing

In the project's own words, from its summary on CORDIS.

In the NOVA ERC PoC project, we present a novel class of semi-synthetic polymyxins as an innovative solution to address the inherent toxicity of the polymyxins family of antibiotics. We here disclose the first candidate compounds of this novel family of antibiotics with potential for use as front-line treatment for multi-drug-resistant Gram-negative bacterial infections. Due to antimicrobial resistance (AMR), a resurgence in the use of polymyxin antibiotics has occurred over the last decade, despite the well characterised and dose-limiting nephrotoxicity associated with these compounds.

Though designated as last-resort antibiotics due to these side effects, the ongoing rise of AMR is forcing clinicians to rely on unsafe antibiotics such as the polymyxins. Increased polymyxin use results in risks for patients and pressure on healthcare systems. Our novel semi-synthetic polymyxins have best-in-class potential given their significantly improved safety profile and offer a superior alternative to current last-resort anti-Gram-negative antibiotics.

Succinctly, the next generation polymyxins we have developed offer key advantages over current last-resort antibiotics: (i) reduced nephrotoxic side effects, (ii) effectiveness against multi-resistant strains with negligible resistance induction, and (iii) ability to be produced at low cost. Moreover, our robust semisynthetic approach will allow us to generate additional analogues in the future. In NOVA, we will explore the technical and commercial potential of our next generation polymyxins.

Specifically, we will validate the first candidate compounds and perform preliminary preclinical toxicity studies in vivo. In parallel, we will evaluate the commercial feasibility of the next generation polymyxins. This entails analysing the market and (existing and emerging) competitors, as well as the IP position and strategy. By the end of the project, we will consolidate the project outcomes in an investor-ready business plan.

Topics

Who is involved

OrganisationCityCountryRole
Universiteit LeidenLeidenNetherlandsCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI